Volume 4.48 | Dec 6

Cord Blood News 4.48 December 6, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
TOP STORY
Short-Term, Long-Term and Paracrine Effect of Human Umbilical Cord-Derived Stem Cells in Lung Injury Prevention and Repair in Experimental Bronchopulmonary Dysplasia
Human umbilical cord-derived perivascular cells and mesenchymal stem cells exert short- and long-term therapeutic benefit without adverse lung effects in an experimental bronchopulmonary dysplasia model and offer new therapeutic options for lung diseases characterized by alveolar damage. [Thorax]
Abstract | Press Release

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

An Efficient Non-Viral Method to Generate Integration-Free Human iPS Cells from Cord Blood and Peripheral Blood Cells
The authors recently reported the efficient generation of human induced pluripotent stem cells (iPSCs) from adult fibroblasts using a combination of plasmids encoding OCT3/4, SOX2, KLF4, L-MYC, LIN28 and shRNA for TP53. They herein report a modified protocol enabling efficient iPSC induction from CD34+ cord blood cells and from peripheral blood isolated from healthy donors using these plasmid vectors. [Stem Cells] Abstract

fsuoAge-Related Impairment of Endothelial Progenitor Cell Migration Correlates with Structural Alterations of Heparan Sulfate Proteoglycans
Researchers demonstrated that OECs isolated from cord blood or peripheral blood samples from young and old individuals exhibit different characteristics in terms of their migratory capacity. [Aging Cell] Abstract

Is the Presence of Six or Fewer Crypt Apoptotic Bodies Sufficient for Diagnosis of Graft versus Host Disease? A Decade of Experience at a Single Institution
To better determine whether the presence of six or fewer apoptotic bodies is sufficient for the diagnosis of graft versus host disease, the authors retrospectively reviewed 78 colon biopsies from 66 patients who received either hematopoietic stem cell or cord blood cell transplantation and whose colon biopsies exhibited apoptotic bodies. [Am J Surg Pathol] Abstract

Unrelated SCT Induces Long-Term Remission in Patients with Blastic Plasmacytoid DC Neoplasm
Blastic plasmacytoid DC neoplasm is a rare hematopoietic malignancy with an aggressive behavior. Researchers evaluated five patients allografted as consolidative treatment with an unrelated donor in first or subsequent remission. Four patients received a reduced intensity-conditioning regimen because of age or co-morbidities. As the stem cell sources, two umbilical cord blood-, two PBSC- and one BM graft were used. [Bone Marrow Transplant] Abstract

Spray- and Laser-Assisted Biomaterial Processing for Fast and Efficient Autologous Cell-Plus-Matrix Tissue Engineering
Investigators introduced and tested the applicability and functionality of two advanced cell-plus-matrix seeding technologies, spray-assisted bioprocessing (SaBP) and laser-assisted bioprocessing, for autologous tissue engineering of bioresorbable artificial grafts. For SaBP, human mesenchymal stem cells, umbilical cord vein endothelial cells and fibrin were simultaneously spray-administered on poly(ε-caprolactone) substrates. [J Tissue Eng Regen Med] Abstract

IL-15 and Macrophage Secretory Factors Facilitate Immune Activation of Neonatal Natural Killer Cells by Lipoteichoic Acid
Scientists investigated the in vitro stimulation of cord blood and adult natural killer cells upon challenge with lipoteichoic acid (LTA), interleukin (IL)-15 and LTA-primed autologous macrophage-conditioned medium, using CD107a and CD69 phenotypes as indicators of activation. [Cytokine] Abstract

DNA Damage Response in CD133+ Stem/Progenitor Cells from Umbilical Cord Blood: Low Level of Endogenous Foci and High Recruitment of 53BP1
Investigators examined repair of radiation-induced DNA double-strand breaks in CD133+ umbilical cord blood cells. [Int J Radiat Biol] Abstract

Differential Distribution of Cathepsin B in Human Umbilical Cord Tissues
Cathepsin B is a major cysteine protease involved in collagen degradation, as well as in the activation of precursor forms of other collagenolytic enzymes and growth factors. Researchers assessed the activity and expression of cathepsin B in the umbilical cord arteries, veins and Wharton’s jelly. [Acta Biochim Pol]
Abstract | Full Article

StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Medium. Come learn more.

REVIEWS
Haploidentical Bone Marrow Transplantation without T-Cell Depletion
This review discusses immune reconstitution and factors associated with clinical outcomes following unmanipulated haploidentical hematopoietic stem cell transplantation, and compares outcomes between unmanipulated haploidentical transplant versus HLA-matched sibling donor transplantation, HLA-matched unrelated donor transplantation, or unrelated double umbilical cord blood transplantation. [Semin Oncol] Abstract
INDUSTRY NEWS

Fate Therapeutics Initiates Phase II Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Fate Therapeutics, Inc. announced the initiation of a randomized, controlled, Phase II multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation for hematologic malignancy. [Fate Therapeutics, Inc.] Press Release

World First – Australian Trial of Cord Blood Seeking to Prevent Type 1 Diabetes
Australian researchers at the Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead will investigate the potential to prevent or delay the onset of type 1 diabetes in high-risk children using cord blood. [Cell Care] Press Release

Roche and the Innovative Medicines Initiative Join Forces to Promote Use of Nobel Prize-Winning Stem Cell Technology to Enhance Drug Development
Roche and the Innovative Medicines Initiative announced the launch of StemBANCC, a new academic-industry partnership that unites ten pharmaceutical companies and 23 academic institutions. Initiated and coordinated by Roche and managed by Oxford University, StemBANCC aims to use human induced pluripotent stem cells as research tools for drug discovery with the goal of using this ground-breaking new technology to develop human disease models and enhance drug development. [Roche] Press Release

POLICY NEWS

NIH Has No Plans to Bring Back Third Grant Submission
Quashing hopes raised by a recent news report, the National Institutes of Health (NIH) announced that it will not reverse a controversial policy that gives researchers only one chance to resubmit a rejected research grant proposal. [National Institutes of Health, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW StemCONN 2013: Realizing the Promise
April 3, 2013
New Haven, United States

View our events page to see a complete list of events in the cord blood community.
JOB OPPORTUNITIES

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Postdoctoral Fellow in Stem Cell Biology (University of Texas Medical School at Houston)

Postdoctoral Research Scientist – Regenerative Stem Cell Research (Oxford NHS Blood and Transplant)

Part-Time Postdoctoral Research Scientist – Regenerative Stem Cell Research (Oxford NHS Blood and Transplant)

Research Technologist – Stem Cells and Cancer (Massachusetts General Hospital & Harvard Medical School)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us